Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion

European Urology

Volumn 46, Issue 2, 2004, Pages 209-215

  Chevreau, Christine ^a   Mazerolles, Catherine ^b   Soulié, Michel ^b   Gaspard, Marie Hélène ^a   Mourey, Loïc ^a   Bujan, Louis ^c   Plante, Pierre ^b,c   Rischmann, Pascal ^b   Bachaud, Jean Marc ^a   Malavaud, Bernard ^b  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b CHU RANGUEIL   (France)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

Adjuvant chemotherapy; BEP; Fertility; Stage I NSGCT

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE; VINBLASTINE;

ACUTE TOXICITY; ADULT; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; EMBRYONAL CARCINOMA; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LONG TERM CARE; MALE; METASTASIS; MORBIDITY; NEUROTOXICITY; NEUTROPENIA; NON SEMINOMATOUS GERMINOMA; ORCHIECTOMY; OTOTOXICITY; PRIORITY JOURNAL; TINNITUS;

EID: 3142572797     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2004.03.022     Document Type: Conference Paper

References (41)

1. Miettinen M., Lindenmayer A.E., Chaubal A. Endothelial cell markers CD31, CD34, and BNH9 antibody to H- and Y-antigens - evaluation of their specificity and sensitivity in the diagnosis of vascular tumors and comparison with von Willebrand factor. Mod. Pathol. 7:1994;82-90
2. Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 5:1982;649-655
3. Heidenreich A., Sesterhenn I.A., Mostofi F.K., Moul J.W. Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis. Cancer. 83:1998;1002-1011
4. Donohue J.P., Thornhill J.A., Foster R.S., Rowland R.G., Bihrle R. Primary retroperitoneal lymph node dissection in clinical stage A non-seminomatous germ cell testis cancer, Review of the Indiana University experience 1965-1989. Br. J. Urol. 71:1993;326-335
5. Foster R.S., Donohue J.P. Retroperitoneal lymph node dissection for the management of clinical stage I nonseminoma. J. Urol. 163:2000;1788-1792
6. Baniel J., Foster R.S., Rowland R.G., Bihrle R., Donohue J.P. Complications of primary retroperitoneal lymph-node dissection for low-stage testicular cancer. World J. Urol. 12:1994;139-142
7. LeBlanc E., Caty A., Dargent D., Querleu D., Mazeman E. Extraperitoneal laparoscopic para-aortic lymph node dissection for early stage nonseminomatous germ cell tumors of the testis with introduction of a nerve sparing technique: description and results. J. Urol. 165:2001;89-92
8. Williams S.D., Stablein D.M., Einhorn L.H., Muggia F.M., Weiss R.B., Donohue J.P., et al. Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N. Engl. J. Med. 317:1987;1433-1438
9. Behnia M., Foster R., Einhorn L.H., Donohue J., Nichols C.R. Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer. the Indiana University experience. Eur. J. Cancer. 36:2000;472-475
10. Droz J.P., van Oosterom A.T. Treatment options in clinical stage I non-seminomatous germ cell tumours of the testis: a wager on the future? A review. Eur. J. Cancer. 29A:1993;1038-1044
11. Albers P., Siener R., Kliesch S., Weissbach L., Krege S., Sparwasser C., et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. J. Clin. Oncol. 21:2003;1505-1512
12. Hermans B.P., Sweeney C.J., Foster R.S., Einhorn L.E., Donohue J.P. Risk of systemic metastases in clinical stage I nonseminoma germ cell testis tumor managed by retroperitoneal lymph node dissection. J. Urol. 163:2000;1721-1724
13. Sweeney C.J., Hermans B.P., Heilman D.K., Foster R.S., Donohue J.P., Einhorn L.H. Results and outcome of retroperitoneal lymph node dissection for clinical stage I embryonal carcinoma - predominant testis cancer. J. Clin. Oncol. 18:2000;358-362
14. Freedman L.S., Parkinson M.C., Jones W.G., Oliver R.T., Peckham M.J., Read G., et al. Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet. 2:1987;294-298
15. Sogani P.C., Perrotti M., Herr H.W., Fair W.R., Thaler H.T., Bosl G. Clinical stage I testis cancer: long-term outcome of patients on surveillance. J. Urol. 159:1998;855-858
16. Pizzocaro G., Zanoni F., Milani A., Salvioni R., Piva L., Pilotti S., et al. Orchiectomy alone in clinical stage I nonseminomatous testis cancer: a critical appraisal. J. Clin. Oncol. 4:1986;35-40
17. Hoskin P., Dilly S., Easton D., Horwich A., Hendry W., Peckham M.J. Prognostic factors in stage I non-seminomatous germ-cell testicular tumors managed by orchiectomy and surveillance: implications for adjuvant chemotherapy. J. Clin. Oncol. 4:1986;1031-1036
18. Thompson P.I., Nixon J., Harvey V.J. Disease relapse in patients with stage I nonseminomatous germ cell tumor of the testis on active surveillance. J. Clin. Oncol. 6:1988;1597-1603
19. Raghavan D., Colls B., Levi J., Fitzharris B., Tattersall M.H., Atkinson C., et al. Surveillance for stage I non-seminomatous germ cell tumours of the testis: the optimal protocol has not yet been defined. Br. J. Urol. 61:1988;522-526
20. Dunphy C.H., Ayala A.G., Swanson D.A., Ro J.Y., Logothetis C. Clinical stage I nonseminomatous and mixed germ cell tumors of the testis. A clinicopathologic study of 93 patients on a surveillance protocol after orchiectomy alone. Cancer. 62:1988;1202-1206
21. Patel S.R., Richardson R.L., Kvols L., Zincke H. Observation after orchiectomy in clinical stage I nonseminomatous germ cell tumor of testis. Mayo Clinic experience. Am. J. Clin. Oncol. 13:1990;379-381
22. Sturgeon J.F., Jewett M.A., Alison R.E., Gospodarowicz M.K., Blend R., Herman S., et al. Surveillance after orchidectomy for patients with clinical stage I nonseminomatous testis tumors. J. Clin. Oncol. 10:1992;564-568
23. Read G., Stenning S.P., Cullen M.H., Parkinson M.C., Horwich A., Kaye S.B., et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J. Clin. Oncol. 10:1992;1762-1768
24. Vergouwe Y., Steyerberg E.W., Eijkemans M.J., Albers P., Habbema J.D. Predictors of occult metastasis in clinical stage I nonseminoma: a systematic review. J. Clin. Oncol. 21:2003;4092-4099
25. Leibovitch I., Foster R.S., Kopecky K.K., Albers P., Ulbright T.M., Donohue J.P. Identification of clinical stage A nonseminomatous testis cancer patients at extremely low risk for metastatic disease: a combined approach using quantitive immunohistochemical, histopathologic, and radiologic assessment. J. Clin. Oncol. 16:1998;261-268
26. Oliver R.T., Raja M.A., Ong J., Gallagher C.J. Pilot study to evaluate impact of a policy of adjuvant chemotherapy for high risk stage 1 malignant teratoma on overall relapse rate of stage 1 cancer patients. J. Urol. 148:1992;1453-1455. discussion 1455-6
27. Studer U.E., Fey M.F., Calderoni A., Kraft R., Mazzucchelli L., Sonntag R.W. Adjuvant chemotherapy after orchiectomy in high-risk patients with clinical stage I non-seminomatous testicular cancer. Eur. Urol. 23:1993;444-449
28. Cullen M.H., Stenning S.P., Parkinson M.C., Fossa S.D., Kaye S.B., Horwich A.H., et al. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J. Clin. Oncol. 14:1996;1106-1113
29. Pont J., Albrecht W., Postner G., Sellner F., Angel K., Holtl W. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J. Clin. Oncol. 14:1996;441-448
30. Klepp O., Dahl O., Flodgren P., Stierner U., Olsson A.M., Oldbring J., et al. Risk-adapted treatment of clinical stage 1 non-seminoma testis cancer. Eur. J. Cancer. 33:1997;1038-1044
31. Bokemeyer C., Schmoll H.J., Kuczyk M.A., Beyer J., Siegert W. Risk of secondary leukemia following high cumulative doses of etoposide during chemotherapy for testicular cancer. J. Natl. Cancer Inst. 87:1995;58-60
32. Wanderas E.H., Fossa S.D., Tretli S. Risk of subsequent non-germ cell cancer after treatment of germ cell cancer in 2006 Norwegian male patients. Eur. J. Cancer. 33:1997;253-262
33. Meinardi M.T., Gietema J.A., van der Graaf W.T., van Veldhuisen D.J., Runne M.A., Sluiter W.J., et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J. Clin. Oncol. 18:2000;1725-1732
34. Herr H.W., Bar-Chama N., O'Sullivan M., Sogani P.C. Paternity in men with stage I testis tumors on surveillance. J. Clin. Oncol. 16:1998;733-734
35. Klein E.A. Open technique for nerve-sparing retroperitoneal lymphadenectomy. Urology. 55:2000;132-135
36. Foster R.S., McNulty A., Rubin L.R., Bennett R., Rowland R.G., Sledge G.W., et al. Fertility considerations in nerve-sparing retroperitoneal lymph-node dissection. World J. Urol. 12:1994;136-138
37. Sonneveld D.J., Schraffordt Koops H., Sleijfer D.T., Hoekstra H.J. Bilateral testicular germ cell tumours in patients with initial stage I disease: prevalence and prognosis - a single centre's 30 years' experience. Eur. J. Cancer. 34:1998;1363-1367
38. Wanderas E.H., Fossa S.D., Tretli S. Risk of a second germ cell cancer after treatment of a primary germ cell cancer in 2201 Norwegian male patients. Eur. J. Cancer. 33:1997;244-252
39. Ansquer Y., Leblanc E., Clough K., Morice P., Dauplat J., Mathevet P., et al. Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study. Cancer. 91:2001;2329-2334
40. Francis R., Bower M., Brunstrom G., Holden L., Newlands E.S., Rustin G.J., et al. Surveillance for stage I testicular germ cell tumours: results and cost benefit analysis of management options. Eur. J. Cancer. 36:2000;1925-1932
41. Bohlen D., Borner M., Sonntag R.W., Fey M.F., Studer U.E. Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. J. Urol. 161:1999;1148-1152